Steve Rucker, MD
Nephrology · Lake Success, NYNPI 1083712806
Payments from drug & device makers
Across 1,139 payments — averaging $58.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$18K
- Vifor Pharma, Inc.$18K
- AstraZeneca$12K
- OPKO Pharmaceuticals, LLC$2K
- Lilly USA, LLC$2K
- Amgen$2K
- plus $12K from 54 others
What the payments were for
- Consulting fees$3,6005%
- Speaking & faculty fees$36,74555%
- Travel & lodging$3,3615%
- Food & beverage$21,51832%
- Education$1,8193%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$19,251
- Veltassa$17,182
- FARXIGA$9,328
- Resolute$601
- XARELTO$600
- AVEIR$306
- Quadra Assura CRT Defibrillator$301
- PURIFIED CORTROPHIN GEL$158
- QUADRA ASSURA$156
- SYMPLICITY G3$131
- BRILINTA$125
- AURYXIA$125
- NEXLIZET$117
- NEXLETOL$117
- LOKELMA$117
How this compares
$67,043 in reported general payments places this provider in the 90th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 13 | $251,027 |
| FarxigaDapagliflozin Propanediol | 162 | $193,275 |
| OzempicSemaglutide | 80 | $86,440 |
| JardianceEmpagliflozin | 59 | $85,285 |
| MounjaroTirzepatide | 50 | $65,185 |
| XareltoRivaroxaban | 61 | $59,466 |
| EliquisApixaban | 56 | $53,234 |
| RayaldeeCalcifediol | 20 | $36,952 |
| MultaqDronedarone Hcl | 22 | $29,273 |
| KerendiaFinerenone | 15 | $28,847 |
| VeltassaPatiromer Calcium Sorbitex | 13 | $23,118 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $17,502 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $15,360 |
| TradjentaLinagliptin | 12 | $14,398 |
| LokelmaSodium Zirconium Cyclosilicate | 16 | $14,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $1,348 | $251,02713 claims |
| AstraZenecaFarxiga, Lokelma | $12,106 | $207,608178 claims |
| Boehringer IngelheimJardiance, Tradjenta | $18,067 | $99,68471 claims |
| Novo NordiskOzempic | $1,208 | $86,44080 claims |
| Lilly USA, LLCMounjaro | $2,122 | $65,18550 claims |
| Johnson & JohnsonXarelto | $816 | $59,46661 claims |
| PfizerEliquis, Prempro | $480 | $55,95468 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $2,367 | $36,95220 claims |
| Sanofi-aventis U.S. LLCMultaq | $306 | $29,27322 claims |
| BayerKerendia | $164 | $28,84715 claims |
| MerckJanumet, Januvia | $333 | $28,51125 claims |
| AbbVieLinzess, Synthroid | $879 | $15,64882 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 nephrology providers in New York.
Other nephrology in Lake Success
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
- David BernardNew York$6M
- Andrew BombackNew York$3.4M
- Pietro CanettaNew York$3.2M
- Robert LynnBronx$2M
- Jodumutt BhatMaspeth$1.5M
- Gerald AppelNew York$1.5M
- David CharytanNew York$1.3M
- Frank CortazarAlbany$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.